Institute of Neurology, Medical University of Vienna, Waehringer Guertel 18-20, Vienna, Austria.
Clin Exp Metastasis. 2013 Jan;30(1):69-81. doi: 10.1007/s10585-012-9510-4. Epub 2012 Jul 1.
New immunomodulatory agents showed promising activity in brain metastases (BM). However, little is known about the inflammatory response in BM. New insights are needed to further guide the development of treatment strategies. We investigated 17 human autoptic tissue specimens of BM from breast cancer (n = 3), non-small cell lung cancer (NSCLC; n = 5), small cell lung cancer (n = 3) and melanoma (n = 6). Immunohistochemical staining for a comprehensive panel of 21 inflammation-associated markers was performed. Results were quantified by manual counting of the various cell populations in three areas of 0.5 mm(2) (intratumoral, peritumoral, control region). Profound microglia activation with marked peritumoral accumulation and some intratumoral infiltration of HLA-DR-positive microglia/macrophages was found. A high proportion of these cells showed strong immunoreactivity for phagocytosis associated markers and MHC class 1, while a smaller subgroup of cells expressed molecules involved in radical production. Only few B- and T-lymphocytes were observed in and around BM. The number of CD8-positive T-cells was not correlated to MHC class 1 expression on tumor cells and only a fraction of T-cells showed Granzym B expression. Melanoma BM had significantly less accumulation of peritumoral microglia than NSCLC BM. The inflammatory pattern was independent from treatment of patients with glucocorticoids or radiation. The inflammatory reaction to BM is mainly characterized by activation of microglia/macrophages and shows pronounced upregulation of markers involved in phagocytosis, but seem to be insufficient in activating adaptive immunity. Treatment strategies aimed at activating specific immunity may potentiate immune attack on tumor cells.
新的免疫调节剂在脑转移瘤 (BM) 中显示出有前景的活性。然而,对于 BM 中的炎症反应知之甚少。需要新的见解来进一步指导治疗策略的发展。我们研究了 17 个人脑 BM 标本,来自乳腺癌 (n=3)、非小细胞肺癌 (NSCLC; n=5)、小细胞肺癌 (n=3) 和黑色素瘤 (n=6)。对 21 种炎症相关标志物的综合面板进行了免疫组织化学染色。通过手动计数 0.5mm² 的三个区域(肿瘤内、肿瘤周围、对照区域)中的各种细胞群来量化结果。发现小胶质细胞明显激活,伴有明显的肿瘤周围堆积和 HLA-DR 阳性小胶质细胞/巨噬细胞的一些肿瘤内浸润。这些细胞中有很大一部分对吞噬作用相关标志物和 MHC 类 1 表现出强烈的免疫反应,而一小部分细胞表达参与自由基产生的分子。在 BM 内外仅观察到少量 B 和 T 淋巴细胞。CD8 阳性 T 细胞的数量与肿瘤细胞上 MHC 类 1 的表达无关,只有一部分 T 细胞表达 Granzyme B。与 NSCLC BM 相比,黑色素瘤 BM 中肿瘤周围小胶质细胞的堆积明显减少。炎症模式与患者接受糖皮质激素或放疗的治疗无关。对 BM 的炎症反应主要表现为小胶质细胞/巨噬细胞的激活,并显示出吞噬作用相关标志物的明显上调,但似乎不足以激活适应性免疫。旨在激活特异性免疫的治疗策略可能增强对肿瘤细胞的免疫攻击。